http://www.bio-equip.cn zh-cn An RSS feed for bio-equip.cn http://www.bio-equip.cn/ensrc.asp?Id=10537 HONG KONG, Mar 31, 2026 - (ACN Newswire) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts.

]]> Fri, 03 Apr 2026 15:47:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10536 1. Literature Information
Research Focus: Application of recombinant rabbit monoclonal antibodies in GeoMx® Digital Spatial Profiler (DSP) technology, their core requirements for DSP compatibility, validation outcomes, and prospects across life science research fields.
Core Innovation: Validation of recombinant rabbit monoclonal antibodies as ideal "molecular detectors&q

]]> Fri, 03 Apr 2026 11:04:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10535 Biotech venture builder focuses on identifying and developing first-in-class therapeutic innovations, exiting at IND stage  
GRAINAU, Germany, April 02, 2026 / Biotech Newswire / --  http://www.bio-equip.cn/ensrc.asp?Id=10534 Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach
HONG KONG, Apr 2, 2026 - (ACN Newswire) - Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights

]]> Fri, 03 Apr 2026 10:46:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10533 Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach
HONG KONG, Apr 2, 2026 - (ACN Newswire) - Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights

]]> Fri, 03 Apr 2026 10:45:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10532 * New preclinical data show NUZ-001 increases activity of multiple protein clearance pathways in neuronal models
* Demonstrates enhanced activity of both autophagy and proteasomal systems, key processes involved in clearing aggregated proteins
* Supports a differentiated, multi-pathway approach targeting disrupted protein homeostasis in neurodegenerative disease
* Findings further characterise t

]]> Thu, 02 Apr 2026 11:02:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10531 * Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
* Integrated downstream workflows to improve productivity and help speed access to critical therapies
* Merck, a leading science and technology company, today announced that it has successfully closed the acquisition of the chromatography business of JSR Life Sciences.



]]> Thu, 02 Apr 2026 10:44:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10530 1. Literature Information
Research Focus: Exploration of ErbB2’s role in tumorigenesis, pathological diagnostic value, impact of gene variants on tumor behavior, milestones in targeted drug development, and the pivotal role of ErbB2 antibodies in precision oncology.
Core Innovation: Validation of ErbB2 as a key oncogenic driver and actionable target—with ErbB2 antibod

]]> Thu, 02 Apr 2026 10:24:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10529 1. Literature Information
Research Focus: Exploration of EpCAM’s structural characteristics, biological functions, signal transduction mechanisms, role in tumor progression, and the therapeutic/diagnostic potential of EpCAM antibodies.
Core Innovation: Validation of EpCAM as a tumor-specific target (highly expressed in epithelial-derived tumors) and demonstration of EpCAM a

]]> Wed, 01 Apr 2026 10:19:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10528 * PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease.
* The collaboration brings together ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience to develop high-quality induced pluripotent stem cell (iPSC)-deri

]]> Wed, 01 Apr 2026 10:09:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10527 Cold Chain Technologies (CCT) has announced its commitment to reaching a Net Zero goal on global emissions, to be achieved by 2050.

The move reflects the organisation’s status as a Scope 3 solutions and services provider and partner to the life science sector, involved in the transportation of millions of doses of medications and vaccines around the world.

The company’s temperature-

]]> Wed, 01 Apr 2026 09:57:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10526 Biotech Fluidics announce the DEGASi® Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC.

Event Date: 11 July 2026 – 12 July 2026 (Saturday-Sunday)
Time: 11 July 2026 (2pm-5pm) 12 July 2026 (8am-5pm)
Place: KB Multi-Purpose Hall, UTAR Sungai Long Campus
Co-Organizers: Binzhou Medical University
 
Introduction:
The TCM Olympiad Cup 2026 is an inter-university Traditional Chinese Medicine (TCM) kno

]]> Tue, 31 Mar 2026 16:40:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10524 1. Literature Information
Research Focus: Exploration of E-Cadherin’s role in cell adhesion, signaling regulation, epithelial-mesenchymal transition (EMT), dual functions in tumor progression, and the applications of E-Cadherin antibodies in research and diagnosis.
Core Innovation: Validation of E-Cadherin as a key regulator of cell adhesion and EMT—with its downregul

]]> Tue, 31 Mar 2026 10:26:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10523 1. Literature Information
Research Focus: Exploration of Desmin’s biological functions in muscle tissue, technical key points of immunohistochemical detection, core diagnostic value in tumor diagnosis, quality assurance systems, clinical decision-making guidance, and technological challenges/opportunities.
Core Innovation: Validation of Desmin antibodies as pivotal tools fo

]]> Tue, 31 Mar 2026 10:18:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10522 1. Literature Information
Research Focus: Exploration of Cyclin D1’s role in cell cycle regulation, its association with tumorigenesis, specific applications of Cyclin D1 antibodies in tumor pathological diagnosis, quality control standardization, and future research directions.
Core Innovation: Validation of Cyclin D1 as a pivotal oncoprotein and diagnostic marker—wi

]]> Tue, 31 Mar 2026 10:10:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10521 1. Literature Information
Research Focus: Exploration of liver fibrosis as a reversible pathological process, the role of type IV collagen (COL IV) as a core early screening marker, and the application of Collagen IV antibodies in non-invasive diagnosis.
Core Innovation: Validation of COL IV as a sensitive indicator for early liver fibrosis (elevated prior to other collagen types) and demo

]]> Tue, 31 Mar 2026 09:58:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10520 Optical Surfaces Ltd is a leading supplier of larger diameter debris shields for high energy laser applications. 

Debris shields are used to prevent damage to critical high precision optical components in beam delivery systems caused by dust, shrapnel and fragments originating from the target in high energy laser experiments. Optical Surfaces debris shields offer a cost-effective solution that exten

]]> Tue, 31 Mar 2026 09:41:00 GMT http://www.bio-equip.cn/ensrc.asp?Id=10519
]]> Mon, 30 Mar 2026 10:46:00 GMT